ABVC BioPharma, Inc. — Q1 2022 Form 10-Q Summary
Reporting period: Three months ended March 31, 2022. Financial statements are unaudited and consolidated.
Business context
ABVC is a clinical-stage biotechnology company developing plant-derived drugs and medical devices, with contract development and manufacturing (CDMO) services through subsidiary BioKey. Management says Q1 revenue was mainly from CDMO services; the company has not generated substantial revenue from its drug and device development business.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $25,660 | $263,150 |
| Gross profit | $23,764 | $261,905 |
| Gross margin | About 92.6% | About 99.5% |
| Operating expenses | $6,242,485 | $1,514,650 |
| Operating loss | $6,218,721 | $1,252,745 |
| Net loss | $6,087,615 | $1,195,323 |
| Net loss per share, basic and diluted | $0.20 | $0.05 |
| Operating cash used | $2,994,257 | $1,413,074 |
Revenue fell about 90% year over year, which management attributed mainly to COVID-19 effects on CDMO activity. Operating expenses increased 312%, driven chiefly by $4.69 million of non-employee stock-based compensation related to stock issued for services and higher R&D spending. R&D expense was $359,404, up from $121,315. Net loss attributable to ABVC and subsidiaries was $5,995,440; the larger consolidated net loss includes noncontrolling interests.
At March 31, 2022, cash and cash equivalents were $2.72 million and restricted cash was $714,652, totaling $3.43 million. Combined cash and restricted cash declined $3.13 million during the quarter. Current assets were $7.99 million, current liabilities $3.66 million, and working capital $4.32 million, down from $5.93 million at year-end 2021. Cash used in investing was $93,220; there was no financing cash flow in Q1.
Total liabilities were $4.71 million. Short-term bank loans totaled $1.61 million; operating lease liabilities were $1.38 million in total ($349,008 current and $1.03 million noncurrent). Convertible note carrying value was zero. Due from related parties was $2.72 million, up from $1.29 million at December 31, 2021. Total assets were $12.07 million and total equity was $7.36 million.
Material changes and significant items
- Common shares outstanding increased from 28,926,322 at year-end 2021 to 30,307,329 at March 31, 2022, largely reflecting shares issued for consulting services. As of May 16, 2022, the company reported 32,307,329 shares outstanding.
- In January 2022, ABVC issued 1,306,007 shares for deferred consulting fees valued at $4,296,763; in March it issued 75,000 shares for consulting services valued at $169,500.
- Related-party advances and lending increased: due from related parties rose by about $1.43 million in the quarter, including additional working-capital loans to BioFirst and BioFirst (Australia). The filing reports these related-party receivables and advances as assets.
- After quarter-end, the company disclosed a May 11, 2022 registered direct offering for 2,000,000 common shares and five-year warrants for 2,000,000 shares at $2.45 per share.
- The company reported that disclosure controls were effective at March 31, 2022 and that there were no changes in internal control over financial reporting during the quarter.
Outlook, risks and contingencies
No quantified revenue, earnings, cash-flow or financing guidance is provided. Management’s strategy is to advance clinical programs and seek licensing or commercialization partners. The disclosed pipeline includes Vitargus (ABV-1701), ABV-1504 for major depressive disorder, ABV-1505 for ADHD, ABV-1601, ABV-1703 and ABV-2002. Development timelines, regulatory outcomes and prospective licensing or royalty income remain uncertain; the company says it has not earned royalties to date.
Management said COVID-19-related lab and research constraints had reduced CDMO demand and could continue to affect operations, supply availability and estimates. Other highlighted risks include the need for sufficient financing, clinical and regulatory execution, competition, market volatility, and uncertainty in future sales and cash flows. The company states that it is not party to legal proceedings expected to have a material adverse effect.
The filing describes a related-party BioLite collaboration requiring milestone payments of up to $100 million. In February 2022, the parties amended the arrangement to allow payments through forgiveness of an equal amount of debt owed by BioLite; the filing says a $5 million payment obligation was to be satisfied by canceling debt BioLite owed ABVC. The terms and execution of this arrangement are material to assess. A potential guarantee of up to approximately $134,000 is also disclosed for a BioLite Japan bank facility.
Important facts for investors to verify
- Whether CDMO revenue and operating cash burn improve, and the company’s available cash runway and financing needs.
- The collectability, terms and recoverability of the $2.72 million due from related parties, including the substantial quarter-on-quarter increase.
- The accounting and economic substance of the $4.69 million non-employee stock compensation expense, consulting share issuances and continuing dilution.
- Progress, costs, trial status and regulatory milestones for the drug and device pipeline; reconcile stated development plans with actual filings and trial disclosures.
- How the $5 million BioLite milestone/debt cancellation was recorded and whether the related-party balances and remaining milestone commitments are clearly reflected.
- The impact of the post-quarter May 2022 share-and-warrant offering on cash, outstanding shares and potential dilution.
- The filing states goodwill was tested and determined impaired as of March 31, 2022, while the balance sheet reports no goodwill; verify the timing and financial-statement treatment, as the filing does not provide a clear Q1 impairment charge.